Foley attorneys filed an amicus brief in the United States District Court for the Southern District of New York related to ACLU v. Myriad regarding subject matter patentability of gene patents specifically on isolated DNA. The authors conclude that the U.S. Congress, U.S. courts and the USPTO, as well as the scientific community and biotechnology industry have long relied upon an understanding that claims directed to “isolated DNA” recite patentable subject matter under 35 U.S.C. §101 and the Constitution. The authors maintain that to hold otherwise would have a dramatic negative effect on biotech research as we know it, and will influence the entire business of biotechnology in ways unforeseen or addressed by the plaintiffs in ACLU v. Myriad”
People
Related News
22 April 2024
Press Releases
Foley Adds IP Partners Ngai Zhang and Drew Schulte, Enhancing Innovative Technology Capabilities
Foley & Lardner LLP announced today that it has bolstered its Innovative Technology Sector and Electronics Practice with the addition of partners Ngai Zhang and Drew Schulte in Washington, D.C. and Miami, respectively.
15 April 2024
Press Releases
Foley Names Andrew Wronski as Manufacturing Sector Chair
Foley & Lardner LLP is pleased to announce that Andrew “Andy” Wronski has been named chair of the firm’s Manufacturing Sector, effective April 15, 2024.
03 April 2024
Press Releases
Foley Continues East Coast Growth with Transactions Partner Joe Bernardi, Strengthening Capabilities in the Technology Sector
Foley & Lardner LLP announced today that the firm has bolstered its Innovative Technology Sector and Private Equity and M&A Practices with the addition of partner Joe Bernardi in Boston.